Key result
Active atorvastatin metabolites reduce Lp(a) oxidation by ~37% compared with vehicle.
Why the study?
Lp(a) levels are linked to increased cardiovascular risk possibly due to oxidized phospholipid content accelerating lipoprotein oxidation, and the antioxidant effects of atorvastatin metabolites compared to other statins were unclear.
Do active hydroxylated metabolites of atorvastatin attenuate the oxidation of Lp(a)-enriched lipoprotein fractions and cholesterol-enriched membranes compared with other statins?
Do active hydroxylated metabolites of atorvastatin attenuate the oxidation of Lp(a)-enriched lipoprotein fractions and cholesterol-enriched membranes compared with other statins?
Answers are grounded in this paper and cite their sources.
Hydroxylated active metabolites of atorvastatin uniquely inhibit the accelerated oxidation of elevated Lp(a) particles in vitro via their phenoxy group, suggesting a potential mechanism to reduce Lp(a) atherogenicity independent of circulating Lp(a) levels.
Lipoprotein(a) [Lp(a)] levels are associated with increased cardiovascular risk, possibly linked to its oxidized phospholipid content that may accelerate lipoprotein oxidation. Attenuating this process could reduce Lp(a) atherogenicity. Atorvastatin is metabolized into 2 hydroxylated metabolites, which account for low-density lipoprotein reduction and potential antioxidant activity. We compared these metabolites' effects to other active statins on oxidation of plasma samples enriched with various levels of Lp(a) or other apolipoprotein B particles, as well as lipid membranes enriched with cholesterol. Lp(a) oxidized more rapidly than other apolipoprotein B particles and accelerated in a nonlinear fashion at levels associated with cardiovascular risk. The metabolites inhibited oxidation of each fraction in contrast to other statins and consistent with cholesterol-enriched membranes. The metabolites' unique phenoxy group facilitated membrane partitioning, leading to free radical scavenging activity as compared with other statins. The antioxidant actions of atorvastatin metabolites may reduce the atherogenicity of Lp(a) in patients independent of their levels.
No takes yet. Share an insight, caveat, or question.
Sherratt et al. (2026) studied Elevated lipoprotein(a) [Lp(a)] and lipoprotein oxidation (n=3). Atorvastatin active hydroxylated metabolites (o-Atorva(m) and p-Atorva(m)) vs. Methanol/ethanol vehicle, atorvastatin parent compound, rosuvastatin, simvastatin, pravastatin, and pitavastatin (10 μM) was evaluated on Reduction in lipoprotein oxidation (malondialdehyde [MDA] levels at peak oxidation time of 2-3 hours) in high-enriched Lp(a) (>60% of total ApoB) (p=<0.01). Active hydroxylated atorvastatin metabolites (10 μM) reduced oxidation (MDA levels) by 32% to 37% in high-enriched Lp(a) fractions and by 54% in model membranes compared to vehicle, unlike other statins.
Synapse has enriched 10 related papers. Consider them for comparative context: